» Articles » PMID: 20842024

Epidemiology and Pattern of Care of Breakthrough Cancer Pain in a Longitudinal Sample of Cancer Patients: Results from the Cancer Pain Outcome Research Study Group

Overview
Journal Clin J Pain
Specialties Neurology
Psychiatry
Date 2010 Sep 16
PMID 20842024
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Breakthrough cancer pain (BTcP) is a frequent event in cancer patients, with a prevalence from 19% to 95%. The reasons for such variability are explained by several factors, including different definitions across studies. In the framework of a wider initiative, we have analyzed the epidemiology of BTcP and identified factors associated with the pattern of care.

Methods: This study reports the results from a multicenter, prospective, nonrandomized, longitudinal study carried out in Italy between 2006 and 2007 on patients with cancer and pain. Transient exacerbations of pain were assessed with 3 different questions, and 1 composite variable to operationally define BTcP was then used as main outcome. After univariate analysis, a logistic model was also fitted to identify prognostic and predictive factors.

Results: One hundred and ten centers recruited 1801 cases of which 40.3% had BTcP at baseline. Most patients did not receive rescue therapy at the time of study inclusion. Univariate analysis identified several associations with clinical variables. A strong association has been also found with the type of recruiting centers, with oncologic wards reporting a somewhat lower proportion of patients with BTcP (-30%) when compared with palliative centers. Patients with BTcP had a high probability of dying (OR=1.4, 95% CI: 1.1-1.7, P-value 0.006) and to change of the opioid with another for analgesic failure or for side effects (OR=1.4, 95% CI: 1.0-1.9, P-value 0.040)

Discussion: These findings confirm the high prevalence of BTcP and substantial undertreatment and identify a few factors associated with prevalence and prognosis.

Citing Articles

Global prevalence and determinant factors of pain, depression, and anxiety among cancer patients: an umbrella review of systematic reviews and meta-analyses.

Getie A, Ayalneh M, Bimerew M BMC Psychiatry. 2025; 25(1):156.

PMID: 39972435 PMC: 11841195. DOI: 10.1186/s12888-025-06599-5.


Definition and Assessment of Paediatric Breakthrough Pain: A Qualitative Interview Study.

Dawson E, Greenfield K, Carter B, Bailey S, Anderson A, Rajapakse D Children (Basel). 2024; 11(4).

PMID: 38671702 PMC: 11049523. DOI: 10.3390/children11040485.


Trajectories and predictors of high-occurrence pain flares in ambulatory cancer patients on opioids.

Meghani S, Quinn R, Robinson A, Chittams J, Vapiwala N, Naylor M JNCI Cancer Spectr. 2024; 8(1).

PMID: 38268502 PMC: 10880071. DOI: 10.1093/jncics/pkae003.


Breakthrough pain among cancer patients at oncology units in Northern Ethiopia; a multi-center study.

Tekie Y, Nigatu Y, Mekonnen W, Berhe Y Front Oncol. 2024; 13:1248921.

PMID: 38264754 PMC: 10805268. DOI: 10.3389/fonc.2023.1248921.


Once again... breakthrough cancer pain: an updated overview.

Mercadante S J Anesth Analg Crit Care. 2023; 3(1):23.

PMID: 37480136 PMC: 10360268. DOI: 10.1186/s44158-023-00101-x.